Lacosamida Mylan

Lacosamide, the active ingredient in Lacosamida Mylan, is a sodium channel blocker presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamida Mylan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic medication used to manage partial‑onset seizures.

Partial‑onset seizures (epilepsy): Reduces the frequency of seizure episodes when used as adjunct therapy. Adjunct therapy for epilepsy: Improves overall seizure control when added to other antiepileptic drugs. Refractory focal seizures: Provides additional seizure reduction in patients not adequately controlled by existing regimens.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac arrhythmias, including PR‑interval prolongation - Suicidal thoughts or behavior

When prescribing lacosamide, clinicians should consider several safety aspects.

Renal impairment: Adjust monitoring as the drug is primarily excreted unchanged in urine. Hepatic impairment: Use with caution; limited data on severe liver disease. Cardiac conduction disorders: Monitor ECG for PR‑interval changes. Pregnancy: Safety not established; weigh potential benefits against risks. Concomitant CNS depressants: May increase sedation or dizziness. Store at ambient temperature: Keep in the original container, protect from moisture and heat.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May lower lacosamide plasma levels. - Other sodium‑channel blockers (e.g., oxcarbazepine): Heightened risk of cardiac conduction abnormalities. - QT‑prolonging agents (e.g., amiodarone): Potential additive effect on cardiac rhythm.

Moderate Interactions (Monitor Closely): - Alcohol: May enhance central nervous system depression. - Anticoagulants (e.g., warfarin): Possible alteration of INR; monitor coagulation parameters.